Concepts (295)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epigenesis, Genetic | 5 | 2024 | 219 | 1.870 |
Why?
|
| Hyaluronoglucosaminidase | 16 | 2013 | 20 | 1.420 |
Why?
|
| Neuroglia | 1 | 2024 | 124 | 0.890 |
Why?
|
| Insulin-Secreting Cells | 1 | 2023 | 28 | 0.870 |
Why?
|
| Hyaluronic Acid | 9 | 2013 | 33 | 0.790 |
Why?
|
| Progeria | 5 | 2015 | 9 | 0.770 |
Why?
|
| Ethanol | 5 | 2022 | 192 | 0.750 |
Why?
|
| Parkinson Disease | 5 | 2022 | 178 | 0.680 |
Why?
|
| Neuroprotective Agents | 5 | 2022 | 245 | 0.660 |
Why?
|
| Lamin Type A | 4 | 2005 | 13 | 0.630 |
Why?
|
| Cannabinoids | 1 | 2018 | 56 | 0.620 |
Why?
|
| Cannabis | 1 | 2018 | 79 | 0.560 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 67 | 0.540 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2016 | 74 | 0.520 |
Why?
|
| Transforming Growth Factor beta | 2 | 2016 | 197 | 0.500 |
Why?
|
| Humans | 44 | 2024 | 37093 | 0.460 |
Why?
|
| Chromosomes, Human, Pair 3 | 4 | 2001 | 9 | 0.430 |
Why?
|
| Evolution, Molecular | 2 | 2013 | 268 | 0.430 |
Why?
|
| Antidepressive Agents | 4 | 2022 | 50 | 0.420 |
Why?
|
| Signal Transduction | 2 | 2016 | 1908 | 0.360 |
Why?
|
| DNA Methylation | 2 | 2024 | 325 | 0.360 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2022 | 14 | 0.340 |
Why?
|
| Central Nervous System Depressants | 3 | 2018 | 37 | 0.340 |
Why?
|
| Depression | 4 | 2019 | 712 | 0.330 |
Why?
|
| Neuroblastoma | 4 | 2022 | 129 | 0.320 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 626 | 0.320 |
Why?
|
| Ejaculation | 1 | 2008 | 11 | 0.310 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 75 | 0.310 |
Why?
|
| Fibroblasts | 6 | 2015 | 272 | 0.310 |
Why?
|
| Erectile Dysfunction | 1 | 2008 | 38 | 0.300 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 1015 | 0.300 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2006 | 13 | 0.270 |
Why?
|
| Lamin Type B | 1 | 2005 | 2 | 0.270 |
Why?
|
| Nicotine | 2 | 2018 | 257 | 0.260 |
Why?
|
| Embryo, Mammalian | 1 | 2005 | 153 | 0.250 |
Why?
|
| Gene Expression | 4 | 2018 | 674 | 0.250 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 36 | 0.240 |
Why?
|
| Animals | 15 | 2024 | 15081 | 0.240 |
Why?
|
| Stem Cells | 1 | 2005 | 141 | 0.240 |
Why?
|
| Mesoderm | 1 | 2004 | 70 | 0.240 |
Why?
|
| Propionates | 1 | 2024 | 26 | 0.240 |
Why?
|
| Valproic Acid | 1 | 2024 | 16 | 0.240 |
Why?
|
| Acetaminophen | 1 | 2024 | 27 | 0.240 |
Why?
|
| Butyrates | 2 | 2022 | 31 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2001 | 6 | 0.230 |
Why?
|
| Olfaction Disorders | 1 | 2023 | 9 | 0.220 |
Why?
|
| Cell Differentiation | 2 | 2005 | 587 | 0.220 |
Why?
|
| Mutation | 2 | 2004 | 1095 | 0.210 |
Why?
|
| Flavonols | 1 | 2022 | 16 | 0.210 |
Why?
|
| Finasteride | 1 | 2022 | 4 | 0.210 |
Why?
|
| Butyric Acid | 1 | 2021 | 18 | 0.200 |
Why?
|
| Receptors, GABA-A | 1 | 2022 | 64 | 0.200 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 2231 | 0.200 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2000 | 63 | 0.200 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2021 | 35 | 0.200 |
Why?
|
| Amino Acid Sequence | 6 | 2004 | 1180 | 0.200 |
Why?
|
| Cell Survival | 3 | 2020 | 864 | 0.200 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 131 | 0.190 |
Why?
|
| Glucose | 1 | 2023 | 230 | 0.190 |
Why?
|
| Neurons | 2 | 2024 | 1175 | 0.180 |
Why?
|
| Peptide Fragments | 2 | 2019 | 308 | 0.180 |
Why?
|
| Tetanus Toxin | 1 | 2019 | 3 | 0.170 |
Why?
|
| Antiparkinson Agents | 1 | 2019 | 12 | 0.170 |
Why?
|
| Nerve Growth Factors | 1 | 2019 | 33 | 0.170 |
Why?
|
| Ketamine | 1 | 2018 | 11 | 0.170 |
Why?
|
| Cytoprotection | 1 | 2018 | 36 | 0.170 |
Why?
|
| Indans | 1 | 2018 | 13 | 0.160 |
Why?
|
| Isoenzymes | 2 | 2002 | 161 | 0.160 |
Why?
|
| Cell Line | 5 | 2005 | 1354 | 0.160 |
Why?
|
| Piperidines | 1 | 2018 | 77 | 0.150 |
Why?
|
| Manganese | 1 | 2018 | 87 | 0.150 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 188 | 0.150 |
Why?
|
| Genome, Human | 2 | 2013 | 135 | 0.150 |
Why?
|
| Caspase 3 | 1 | 2018 | 207 | 0.150 |
Why?
|
| Imipramine | 1 | 2017 | 8 | 0.150 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 12 | 0.150 |
Why?
|
| Marijuana Abuse | 1 | 2018 | 91 | 0.150 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2017 | 17 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 149 | 0.140 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2017 | 39 | 0.140 |
Why?
|
| Vasodilator Agents | 2 | 2008 | 56 | 0.140 |
Why?
|
| Iron | 1 | 2018 | 225 | 0.140 |
Why?
|
| Molecular Sequence Data | 5 | 2001 | 1568 | 0.140 |
Why?
|
| Neurotransmitter Agents | 1 | 2017 | 63 | 0.140 |
Why?
|
| Sclera | 1 | 2016 | 6 | 0.140 |
Why?
|
| Psychosurgery | 1 | 2016 | 1 | 0.140 |
Why?
|
| Sterilization | 1 | 2016 | 3 | 0.140 |
Why?
|
| Hungary | 1 | 2016 | 9 | 0.140 |
Why?
|
| Portugal | 1 | 2016 | 9 | 0.140 |
Why?
|
| Trabecular Meshwork | 1 | 2016 | 9 | 0.140 |
Why?
|
| History, 19th Century | 1 | 2016 | 24 | 0.140 |
Why?
|
| Nicotinic Agonists | 1 | 2017 | 75 | 0.140 |
Why?
|
| Optic Nerve | 1 | 2016 | 28 | 0.140 |
Why?
|
| Aqueous Humor | 1 | 2016 | 18 | 0.140 |
Why?
|
| Ethics, Medical | 1 | 2016 | 18 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 35 | 0.140 |
Why?
|
| Microarray Analysis | 1 | 2016 | 61 | 0.140 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2017 | 107 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2016 | 117 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 1997 | 251 | 0.130 |
Why?
|
| Intraocular Pressure | 1 | 2016 | 112 | 0.130 |
Why?
|
| Mucopolysaccharidoses | 2 | 2008 | 2 | 0.130 |
Why?
|
| Bacteria | 1 | 2018 | 255 | 0.130 |
Why?
|
| Cell Nucleus | 2 | 2010 | 366 | 0.130 |
Why?
|
| Fibrosis | 1 | 2016 | 159 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1039 | 0.130 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2001 | 269 | 0.130 |
Why?
|
| Computational Biology | 1 | 2016 | 293 | 0.120 |
Why?
|
| Chondroitin | 1 | 2013 | 1 | 0.110 |
Why?
|
| Male | 10 | 2022 | 20025 | 0.110 |
Why?
|
| Chitin | 1 | 2013 | 19 | 0.110 |
Why?
|
| Enzyme Inhibitors | 4 | 2010 | 433 | 0.110 |
Why?
|
| Selection Bias | 1 | 2012 | 11 | 0.110 |
Why?
|
| Peer Review, Research | 1 | 2012 | 10 | 0.110 |
Why?
|
| Editorial Policies | 1 | 2012 | 13 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2008 | 1369 | 0.110 |
Why?
|
| Science | 1 | 2012 | 18 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 49 | 0.100 |
Why?
|
| Aging | 2 | 2015 | 664 | 0.100 |
Why?
|
| Depressive Disorder | 2 | 2019 | 174 | 0.100 |
Why?
|
| Syndrome | 3 | 2010 | 74 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 730 | 0.100 |
Why?
|
| Farnesyltranstransferase | 1 | 2010 | 4 | 0.090 |
Why?
|
| Phenotype | 3 | 2015 | 689 | 0.090 |
Why?
|
| Extracellular Matrix | 2 | 2004 | 115 | 0.090 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 35 | 0.090 |
Why?
|
| Mice | 5 | 2008 | 5913 | 0.090 |
Why?
|
| DNA Repair | 1 | 2010 | 188 | 0.080 |
Why?
|
| Blotting, Northern | 2 | 1999 | 150 | 0.080 |
Why?
|
| Skin | 2 | 2000 | 174 | 0.080 |
Why?
|
| Rats, Inbred WKY | 2 | 2019 | 23 | 0.080 |
Why?
|
| Orgasm | 1 | 2008 | 2 | 0.080 |
Why?
|
| Osteoarthritis | 1 | 2008 | 20 | 0.080 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 34 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2004 | 623 | 0.080 |
Why?
|
| Rats, Wistar | 2 | 2018 | 233 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2004 | 93 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 628 | 0.070 |
Why?
|
| Base Sequence | 3 | 2004 | 997 | 0.070 |
Why?
|
| Child | 3 | 2022 | 3131 | 0.070 |
Why?
|
| Rats | 3 | 2019 | 3483 | 0.070 |
Why?
|
| Citalopram | 1 | 2006 | 3 | 0.070 |
Why?
|
| Ergolines | 1 | 2006 | 2 | 0.070 |
Why?
|
| Sertraline | 1 | 2006 | 7 | 0.070 |
Why?
|
| Selegiline | 1 | 2006 | 6 | 0.070 |
Why?
|
| Fluoxetine | 1 | 2006 | 11 | 0.070 |
Why?
|
| Bupropion | 1 | 2006 | 12 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1371 | 0.070 |
Why?
|
| Adult | 5 | 2015 | 11712 | 0.070 |
Why?
|
| Purines | 1 | 2006 | 38 | 0.070 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 30 | 0.070 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2006 | 25 | 0.070 |
Why?
|
| Muscle Cells | 1 | 2005 | 11 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2008 | 174 | 0.070 |
Why?
|
| Sulfones | 1 | 2006 | 44 | 0.070 |
Why?
|
| Female | 8 | 2017 | 20969 | 0.070 |
Why?
|
| Plants, Medicinal | 1 | 2006 | 68 | 0.060 |
Why?
|
| Androgens | 1 | 2006 | 89 | 0.060 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2006 | 77 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 111 | 0.060 |
Why?
|
| Cell Lineage | 1 | 2005 | 90 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2006 | 63 | 0.060 |
Why?
|
| Testosterone | 1 | 2006 | 193 | 0.060 |
Why?
|
| Hippocampus | 2 | 2019 | 561 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2004 | 513 | 0.060 |
Why?
|
| Anxiety | 2 | 2015 | 754 | 0.060 |
Why?
|
| Heterozygote | 1 | 2004 | 93 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 502 | 0.060 |
Why?
|
| Substrate Specificity | 3 | 2001 | 212 | 0.060 |
Why?
|
| Werner Syndrome | 1 | 2003 | 3 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2004 | 132 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2008 | 933 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 307 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 252 | 0.060 |
Why?
|
| Point Mutation | 1 | 2003 | 93 | 0.050 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2022 | 79 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2003 | 53 | 0.050 |
Why?
|
| Chondrogenesis | 1 | 2002 | 3 | 0.050 |
Why?
|
| Homozygote | 2 | 2003 | 77 | 0.050 |
Why?
|
| RNA | 1 | 2004 | 241 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2004 | 435 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 5363 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 70 | 0.050 |
Why?
|
| Pseudogenes | 1 | 2001 | 11 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2001 | 24 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2015 | 1518 | 0.050 |
Why?
|
| Genotype | 1 | 2004 | 730 | 0.050 |
Why?
|
| Multigene Family | 1 | 2001 | 106 | 0.050 |
Why?
|
| Species Specificity | 1 | 2001 | 245 | 0.050 |
Why?
|
| Dopamine | 1 | 2022 | 245 | 0.050 |
Why?
|
| Time Factors | 1 | 2006 | 1742 | 0.050 |
Why?
|
| Genome | 1 | 2001 | 125 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 1998 | 325 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 515 | 0.050 |
Why?
|
| RNA Precursors | 1 | 2000 | 27 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2000 | 85 | 0.040 |
Why?
|
| Gene Library | 1 | 1999 | 57 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1130 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2004 | 681 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 267 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 78 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 168 | 0.040 |
Why?
|
| Intestines | 1 | 2018 | 64 | 0.040 |
Why?
|
| Locomotion | 1 | 2019 | 97 | 0.040 |
Why?
|
| Phylogeny | 1 | 2001 | 644 | 0.040 |
Why?
|
| Sequence Tagged Sites | 1 | 1998 | 4 | 0.040 |
Why?
|
| Databases, Factual | 1 | 1999 | 291 | 0.040 |
Why?
|
| Feces | 1 | 2018 | 111 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 178 | 0.040 |
Why?
|
| Corpus Striatum | 1 | 2019 | 104 | 0.040 |
Why?
|
| Models, Biological | 1 | 2001 | 677 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 1998 | 119 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 177 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 1997 | 49 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 1997 | 67 | 0.040 |
Why?
|
| Fluoresceins | 1 | 2017 | 27 | 0.040 |
Why?
|
| Leeches | 1 | 1997 | 1 | 0.040 |
Why?
|
| Invertebrates | 1 | 1997 | 15 | 0.040 |
Why?
|
| Eukaryota | 1 | 1997 | 20 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 623 | 0.040 |
Why?
|
| Swimming | 1 | 2017 | 38 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2017 | 98 | 0.040 |
Why?
|
| Venoms | 1 | 1997 | 15 | 0.040 |
Why?
|
| Viruses | 1 | 1997 | 36 | 0.040 |
Why?
|
| Bacteriophages | 1 | 1997 | 44 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 448 | 0.030 |
Why?
|
| Motor Activity | 1 | 2019 | 418 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 290 | 0.030 |
Why?
|
| Fungi | 1 | 1997 | 89 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 93 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 480 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 358 | 0.030 |
Why?
|
| Middle Aged | 1 | 2008 | 10129 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 519 | 0.030 |
Why?
|
| Observer Variation | 1 | 2012 | 52 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1398 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 1997 | 540 | 0.030 |
Why?
|
| Neoplasms | 1 | 2001 | 1103 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1033 | 0.020 |
Why?
|
| Exons | 2 | 2003 | 88 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 1346 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2001 | 364 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1198 | 0.020 |
Why?
|
| Joints | 1 | 2008 | 7 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2000 | 191 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2008 | 22 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2008 | 38 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 3562 | 0.020 |
Why?
|
| Uniparental Disomy | 1 | 2003 | 3 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 11 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2003 | 10 | 0.010 |
Why?
|
| Electrophoresis | 1 | 2003 | 22 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 79 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 103 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 189 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2002 | 90 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 122 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2002 | 150 | 0.010 |
Why?
|
| Staurosporine | 1 | 2002 | 38 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 45 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 75 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 448 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2002 | 95 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 562 | 0.010 |
Why?
|
| Microchemistry | 1 | 2001 | 10 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2001 | 21 | 0.010 |
Why?
|
| Biotin | 1 | 2001 | 24 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 421 | 0.010 |
Why?
|
| Gels | 1 | 2001 | 42 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 381 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 201 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2000 | 53 | 0.010 |
Why?
|
| Skin Absorption | 1 | 2000 | 15 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1999 | 8 | 0.010 |
Why?
|
| Epidermis | 1 | 2000 | 24 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1999 | 52 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 46 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 41 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1999 | 35 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2000 | 77 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2000 | 108 | 0.010 |
Why?
|
| Introns | 1 | 2000 | 75 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1999 | 167 | 0.010 |
Why?
|
| Testis | 1 | 2001 | 187 | 0.010 |
Why?
|
| Cell Count | 1 | 1999 | 135 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 477 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 142 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 708 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2001 | 492 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 444 | 0.010 |
Why?
|
| Insulin | 1 | 1999 | 236 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1997 | 26 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 1207 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2000 | 515 | 0.010 |
Why?
|